The Effectiveness of Cancer Immune Checkpoint Inhibitor Retreatment and Rechallenge—A Systematic Review

The Effectiveness of Cancer Immune Checkpoint Inhibitor Retreatment and Rechallenge—A Systematic Review

Despite a great success of immunotherapy in cancer treatment, a great number of patients will become resistant. This review summarizes recent reports on immune checkpoint inhibitor retreatment or rechallenge in order to overcome primary resistance. The systematic review was performed according to PR...

Full description

Bibliographic Details
Main Authors:	Adrian Perdyan, Bartosz Kamil Sobocki, Amar Balihodzic, Anna Dąbrowska, Justyna Kacperczyk, Jacek Rutkowski
Format:	Article
Language:	English
Published:	MDPI AG 2023-07-01
Series:	Cancers
Subjects:	immune checkpoint inhibitors retreatment rechallenge oncology melanoma
Online Access:	https://www.mdpi.com/2072-6694/15/13/3490

Similar Items

Immune Checkpoint Inhibitors-Associated Myocarditis: Diagnosis, Treatment and Current Status on Rechallenge
by: Federica Frascaro, et al.
Published: (2023-12-01)

Efficacy of Immune Checkpoint Inhibitor (ICI) Rechallenge in Advanced Melanoma Patients’ Responders to a First Course of ICI: A Multicenter National Retrospective Study of the French Group of Skin Cancers (Groupe de Cancérologie Cutanée, GCC)
by: Charlée Nardin, et al.
Published: (2023-07-01)

Efficacy of NSCLC Rechallenge with Immune Checkpoint Inhibitors following Disease Progression or Relapse
by: Maria Effrosyni Livanou, et al.
Published: (2024-03-01)

Immune-Related Adverse Events (irAE) in Cancer Immune Checkpoint Inhibitors (ICI) and Survival Outcomes Correlation: To Rechallenge or Not?
by: Heidar J. Albandar, et al.
Published: (2021-02-01)

Immune Checkpoint Inhibitor Rechallenge in Renal Cell Carcinoma: Current Evidence and Future Directions
by: Enrico Sammarco, et al.
Published: (2023-06-01)

Immunotherapy Resumption/Rechallenge in Melanoma Patients after Toxicity: Do We Have Another Chance?
by: Sofia España Fernandez, et al.
Published: (2023-03-01)

Melanoma: BRAFi Rechallenge
by: Christoforos S. Kosmidis, et al.
Published: (2023-05-01)

Clinical characteristics and novel strategies of immune checkpoint inhibitor rechallenge therapy for non-small cell lung cancer: a comprehensive review
by: Hao Zhang, et al.
Published: (2024-01-01)

Efficacy and safety of immune checkpoint inhibitor rechallenge in non‐small cell lung cancer: A systematic review and meta‐analysis
by: Yu Feng, et al.
Published: (2023-09-01)

Successful immune checkpoint inhibitor‐based rechallenge in a patient with advanced esophageal squamous cell cancer: A case report
by: Yanhong Yao, et al.
Published: (2022-02-01)

Case Report: Successful immune checkpoint inhibitor-based rechallenge in a patient with advanced renal clear cell cancer
by: Shengxiu He, et al.
Published: (2023-10-01)

Efficacy and Safety of Rechallenge with BRAF/MEK Inhibitors in Advanced Melanoma Patients: A Systematic Review and Meta-Analysis
by: Jonathan N. Priantti, et al.
Published: (2023-07-01)

Two Cases of Durable and Deep Responses to Immune Checkpoint Inhibition-Refractory Metastatic Melanoma after Addition of Camu Camu Prebiotic
by: Steph A. Pang, et al.
Published: (2023-08-01)

Immune checkpoint inhibitor-induced colitis with endoscopic evaluation in Chinese cancer patients: a single-centre retrospective study
by: Furong Kou, et al.
Published: (2023-11-01)

Long-Term Toxicities of Immune Checkpoint Inhibitor (ICI) in Melanoma Patients
by: Justin Tong, et al.
Published: (2022-10-01)

Retreatment with immunotherapy in a patient with hepatocellular carcinoma who received immune checkpoint inhibitors after primary curative treatment: a case report
by: Tao Wang, et al.
Published: (2024-04-01)

Successful rechallenge with avelumab in a patient with advanced Merkel cell carcinoma who presented pembrolizumab‐induced myositis
by: Clémence Bertold, et al.
Published: (2023-12-01)

Successful rechallenge with cetuximab after progression with nivolumab for recurrent cervical lymph node metastasis from carcinoma of the tongue
by: Yasuyuki Asada, et al.
Published: (2021-07-01)

Mechanism and Management of Checkpoint Inhibitor-Related Toxicities in Genitourinary Cancers
by: Haoran Li, et al.
Published: (2022-05-01)

Biomarker-Guided Anti-EGFR Rechallenge Therapy in Metastatic Colorectal Cancer
by: Davide Ciardiello, et al.
Published: (2021-04-01)

Lenvatinib rechallenge in a patient with advanced thymic carcinoma: A case report
by: Yuto Terashima, et al.
Published: (2022-12-01)

Effectiveness of Four Rotary Retreatment Instruments During Root Canal Retreatment
by: Ali Cagin Yucel, et al.
Published: (2015-02-01)

Trametinib-Resistant Melanoma Cells Displaying MITF<sup>high</sup>/NGFR<sup>low</sup>/IL-8<sup>low</sup> Phenotype Are Highly Responsive to Alternating Periods of Drug Withdrawal and Drug Rechallenge
by: Paulina Koziej, et al.
Published: (2023-04-01)

Long-term Survival after Lapatinib Rechallenge in Isolated Brain Metastasis of HER2-positive Breast Cancer
by: Bülent Karagöz, et al.
Published: (2015-01-01)

Efficacy of Retreatment with Oxaliplatin-Based Regimens in Metastatic Colorectal Cancer Patients: The RETROX-CRC Retrospective Study
by: Alessio Amatu, et al.
Published: (2022-02-01)

Comparison of retreatment times of root fillings with different sealers by different retreatment techniques
by: Elif Kalyoncuoğlu
Published: (2016-01-01)

Taxane rechallenge during metastatic disease in HER-2 negative breast cancer patients: Clinical activity, tolerance and survival results
by: Manon Réda, et al.
Published: (2023-04-01)

Endodontist's dilemma: Retreat or extract?
by: Girija Abhijeet Kolarkar, et al.
Published: (2020-01-01)

Comparing the efficacy of regorafenib and 5-fluorouracil-based rechallenge chemotherapy in the third-line treatment of metastatic colorectal cancer
by: Elif Şenocak Taşçı, et al.
Published: (2024-01-01)

Multicenter, Retrospective Study to Evaluate Necitumumab Plus Cisplatin and Gemcitabine After Immune Checkpoint Inhibitors in Advanced Squamous Cell Lung Cancer in Japan: The NINJA Study
by: Yasunori Murata, MD, PhD, et al.
Published: (2023-12-01)

Successful mRNA SARS-Cov-2 vaccine rechallenge after a first episode of immune thrombocytopenic purpura
by: Mathilde Chanut, et al.
Published: (2022-05-01)

The Role of Regulatory T Cells in Cancer Treatment Resistance
by: Anna Dąbrowska, et al.
Published: (2023-09-01)

Rechallenge with anti-EGFR therapy to extend the continuum of care in patients with metastatic colorectal cancer
by: Chiara Cremolini, et al.
Published: (2023-02-01)

Disease progression status during initial immune checkpoint inhibitor (ICI) affects the clinical outcome of ICI retreatment in advanced non‐small cell lung cancer patients
by: Masahiro Torasawa, et al.
Published: (2023-06-01)

Review of Immune-Related Adverse Events (irAEs) in Non-Small-Cell Lung Cancer (NSCLC)—Their Incidence, Management, Multiorgan irAEs, and Rechallenge
by: Raju Vaddepally, et al.
Published: (2022-03-01)

Cetuximab as third‐line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS/BRAF wild‐type circulating tumor DNA: Individual patient data pooled analysis of CRICKET and CAVE trials
by: G. Martini, et al.
Published: (2023-04-01)

Skin Toxicity as Predictor of Survival in Refractory Patients with <i>RAS</i> Wild-Type Metastatic Colorectal Cancer Treated with Cetuximab and Avelumab (CAVE) as Rechallenge Strategy
by: Davide Ciardiello, et al.
Published: (2021-11-01)

Rechallenge in idiosyncratic drug-induced liver injury: An analysis of cases in two large prospective registries according to existing definitions
by: J.M. Pinazo-Bandera, et al.
Published: (2024-05-01)

Does the Rechallenge with Another CDK 4/6 Inhibitor in Breast Cancer Work? A Case Report and Literature Review
by: Ioana-Miruna Stanciu, et al.
Published: (2023-04-01)

Anti-EGFR Reintroduction and Rechallenge in Metastatic Colorectal Cancer (mCRC): A Real-World Analysis
by: Martin S. Schulz, et al.
Published: (2022-03-01)